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Abstract CCN3 is a member of the CCN family of cell
growth and differentiation regulators that play key roles
during embryonic development, and are associated with
severe human pathologies. The level of CCN genes’
expression is of prognostic value in several types of tumors.
In the present manuscript, we report the isolation and
characterization of a new set of antibodies targeted against
each individual module of the human CCN3 protein. The
need for module-specific antibodies stemmed from recent
reports indicating that the expression of truncated CCN
variant proteins was associated with development of
cancers. Each of the four CCN3 modules were expressed
as GST fusion proteins and used for rabbits immunization.
Polyclonal IgGs purified by two rounds of affinity–
chromatography specifically detected both the individual
CCN3 domains and the full length CCN3 protein expressed
in mammalian cell lines and tissues, as well as recombinant
full length and truncated CCN3 proteins. The purified
module-specific antibodies were successfully used for
Western blotting, immunoprecipitation, immunofluores-
cence and immunocytochemistry. These antibodies permit-
ted the detection of CCN3 proteins under native and
denaturing conditions, and confirmed the sublocalisation
of CCN3 proteins in the extracellular compartment, at the
cell membrane, in the cytoplasm and in the nucleus of
positive cells. Immunocytochemistry and Western blotting
studies performed with the module-specific antibodies
identified truncated CCN3 proteins in kidney tumor
samples. The detection of these rearranged variants pro-
vides clues for their involvement in tumorigenesis. There-
fore, these antibodies constitute unique tools for the
identification of truncated CCN3 proteins in human tissues
and may be of great interest in molecular medicine.
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Introduction
The CCN3 protein is one of the three founders of the CCN
family, which contains six members in human. The CCN
proteins are key regulators of embryonic development
(reviewed in Planque and Perbal 2003a; Perbal 2004;
Rachfal and Brigstock 2005; Perbal and Takigawa 2005).
They are involved in various cellular processes including
proliferation, differentiation, survival, adhesion and migra-
tion. In the adult, the CCN proteins participate in the repair
of injured tissues. Deregulations of expression of the CCN
proteins have been described in fibrotic and cancer pathol-
ogies (reviewed in Planque and Perbal 2003b; Perbal 2004;
Rachfal and Brigstock 2005). The CCN proteins are secreted
factors of 35–48 kDa that contain four structural modules:
(a) an insulin-like growth factor binding protein (IGFBP)-
type motif, (b) a Von Willebrand type C (VWC) domain
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likely responsible for oligomerization, (c) a thrombospondin
type 1 (TSP1) repeat, responsible for the interaction with
extracellular matrix proteins, and (d) a carboxy-terminal
module (CT) that contains a cystine-knot motif.
CCN3 exerts antiproliferative functions on both normal
and tumor cells of various origins (Planque et al. 2005;
Fukunaga-Kalabis et al. 2006; McCallum et al. 2006; Van
Roeyen et al. 2007). CCN3 also modulates cell adhesion
and migration (Benini et al. 2005), and CCN3 expression in
primary Ewing’s tumors was associated with higher risk of
developing metastasis (Manara et al. 2002). These results
suggest a critical role for CCN3 in cancer progression. In
agreement with these data, CCN3 expression was correlated
with good or bad prognosis of survival in various types of
cancers (reviewed in Planque et al. 2005). During embry-
onic development in mammalians, preferential sites of
CCN3 expression included central nervous system, urogen-
ital tract, and musculo-skeletal apparatus (reviewed in
Planque et al. 2005 and Perbal and Planque 2006). In the
adult, CCN3 expression persists in some of these sites
(Perbal and Planque 2006).
In addition to the 54 kDa full-length secreted CCN3
protein, an amino-truncated form of about 30 kDa was
observed in various embryonic and adult mammalian tissues
(Ellis et al. 2000; Kocialkowski et al. 2001; Su et al. 2001), in
diverse biological fluids (Burren et al. 1999), as well as in
culture supernatants and cell extracts of normal and tumor
cells (Chevalier et al. 1998; Perbal 1999; Perbal et al. 1999;
Thomopoulos et al. 2001; Fu et al. 2004; Kyurkchiev et al.
2004). Sequencing of the truncated CCN3 form produce by
baculovirus-infected cells indicated that it contained the
TSP1 and CT modules (Perbal et al. 1999). It was postulated
that this variant might be generated by proteolytic cleavage
of the full-length secreted form (Perbal 2001). The immuno-
logical detection of CCN3 proteins used polyclonal anti-
bodies targeted against the last 19 C-terminal amino acids.
Because truncated CCN protein variants lacking internal
modules were associated with tumor development (Joliot et al.
1992; Tanaka et al. 2001), we have prepared polyclonal
antibodies targeted against each of the four modules of the
CCN3 protein in order to study whether deletion variant
CCN3 proteins are expressed in human tumor tissues. For
this purpose, each exon of the human ccn3 gene was cloned
into a pGEX vector and the corresponding GST fusion
proteins were used as antigens for rabbit immunization after
they were purified by affinity chromatography. The
module-specific IgGs reacted with each CCN3 module,
either individually or in the context of the full-length
protein. The four IgGs preparations were successfully
validated for Western blot analysis, immunofluorescent
staining and immunocytochemistry, therefore providing
unique tools for immunological identification of truncated
CCN3 proteins in normal and pathological samples.
Material and methods
Preparation of the immunogenic proteins and purification
of the immune sera
The cDNAs of exons encoding each of the four human CCN3
modules were cloned into the pGEX-4T1 vector (Amersham –
GE Healthcare) and the corresponding recombinant plasmids
were further used to transform E. coli BL21.
GST-NH fusion proteins (nomenclature depicted in
Fig. 1a) were purified by affinity chromatography on
Sepharose beads as previously described (Bleau et al.
2007). GST fusion proteins were dialyzed against 10 mM
NH4HCO3 and quantified by SDS-PAGE. Proteins were
revealed by Coomassie Blue and silver staining. Protein
concentrations were estimated by comparison with a
Bovine Serum Albumin standard loaded onto the same
gel. Of each GST-NH fusion protein preparation, 1.5 mg
were used for rabbit immunization (Agro-Bio, La Ferté St
Aubin, France). Rabbits were injected five times with
250 μg of purified GST-NH proteins. Three bleedings of
20–25 ml were then performed, and the rabbits were
boosted with another 250 μg of antigens. IgG were purified
from the immune sera by affinity chromatography on
Protein A Sepharose beads. Briefly, nProtein A Sepharose
4 Fast Flow (Amersham – GE Healthcare) was equilibrated
with 20 mM Tris pH 8.0. Anti-NH sera were loaded on the
Protein A column and then washed with 20 mM Tris
pH 8.0 and 20 mM glycine pH 5.0. IgG were eluted using
Fig. 1 Preparation of the GST fusion proteins used as immunogens.
a Schematic diagram depicting modular organization of the CCN3
protein and the nomenclature used in this manuscript. cDNAs of the
human CCN3 exons (NH2, NH3, NH4 and NH5) were inserted in the
pGEX4T1 vector downstream to the GST gene. b Control of purity
and quantification of the immunogen proteins. Coomassie Blue
staining of the SDS-PAGE gel. GST-NH proteins were extracted and
purified from E. coli BL21 bacteria using glutathione affinity
chromatography. MW: protein molecular weight marker (kDa)
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100 mM glycine pH 2.5 and neutralized with 1 M Tris
pH 8.0. Fractions were pooled, and concentrated on
Vivaspin concentrator (Vivascience).
Removal of anti-GST antibodies was performed by
affinity chromatography. Purified GST protein was coupled
to CNBr-activated Sepharose 4B PD-10 columns according
to the protocol recommended by the manufacturer (Amer-
sham – GE Healthcare). The IgG preparations were loaded
on these columns, and absorbance of the collected fractions
was measured at 280 nm. Anti-NH IgG were in the flow-
through fractions while anti-GST IgG were adsorbed on the
beads. Flow-through fractions were pooled and concentrat-
ed with Vivaspin concentrators (Vivascience).
Construction of expression vectors, production
and purification of various recombinant proteins
pTEF-MF yeast expression vectors (Dualsystems Biotech)
were used to produce each individual modules of the human
CCN3 protein in a tag-free version or with a 6-Histidine tag
at their amino-terminus (Bleau et al. 2007). This system
allows secretion of the recombinant proteins in yeast culture
medium. The non-tagged recombinant NH proteins were
purified by immuno-affinity chromatography (Bleau et al.
2007). 6HIS-tagged constructs were purified using Ni-NTA
purification system according to the manufacturer’s instruc-
tions (Invitrogen). Proteins were eluted with 500 mM
imidazole. Recombinant Y-NH proteins were dialyzed
overnight at 4°C against 10 mM NH4HCO3, lyophilized,
and frozen until use. For biochemical assays, the proteins
were usually dissolved in PBS. Quantification was per-
formed after SDS-PAGE followed by silver staining of the
gels.
The construction of pcDNA vectors expressing non-
secretedMyc-tagged CCN3 variants was previously described
(Planque et al. 2006). To generate secreted Myc-tagged
variants (sMNH, Fig. 2a), the CCN3 signal peptide was
PCR-amplified and inserted at the HindIII/BamHI sites of
pMNH25, -NH24, -NH35 and -NH45. These constructs
allow secretion of the sMNH proteins in cell culture medium
when introduced into mammalian cells.
Culture and transfection of mammalian cell lines
The G59 glioblastoma cell line was originally isolated and
provided by Dr M. Westphal, and has been described
previously (Li et al. 1996). G59 were grown in Dulbecco’s
Modified Eagle Medium (DMEM; Sigma) supplemented
with 10% fetal calf serum (FCS) Sigma) and L-Glutamin–
Penicillin–Streptomycin mix (Sigma; complete medium).
The G540 cells isolated after transfection with the pCMV-
CCN3 plasmid (pCMV82) express the human CCN3 protein
(Gupta et al. 2001; Bleau et al. 2007). G59 cells were also
transfected with psMNH25, psMNH35, psMNH24,
psMNH45 (nomenclature depicted Fig. 2a) or pcDNA
DNAs. Cell transfections were performed in 3.5 cm dishes
in OPTIMEM medium with Lipofectamin 2000 (Invitrogen)
according to the manufacturer’s recommendations. For each
dish, 2 μg of DNA were mixed with 5 μl of Lipofectamin
2000 in a final volume of 1 ml of OPTIMEM, and incubated
for 20 min at room temperature before being applied to cell
cultures. Seventy two h after transfection, cell lysates and
culture supernatants were tested for the expression of the
recombinant proteins by immunoblotting with mouse mono-
clonal anti-Myc antibodies (Roche; 1:2000).
Human adenocortical carcinoma NCI H295R (American
Type Cell Collection) cell line was cultured in DMEM-F12
(Sigma) supplemented with 2.5% of Nu serum (Invitrogen)
and ITS+ supplement (Sigma). These cells express high
levels of CCN3 (Thomopoulos et al. 2001).
For immunofluorescence detection, G59 and Baby
Hamster Kidney 21 (BHK21) cells were seeded on cover-
slips in 24-well plates. For transfection, 600 ng of DNAs
were incubated with 2 μl of EXGEN500 (Euromedex) in a
final volume of 30 μl of 150 mM NaCl according to the
manufacturer’s instructions.
Western blotting
Western blotting analyses were performed both with cell
culture supernatants and cell lysates.
Laemmli buffer was directly added to 25 μl of
conditioned media from G59 cells secreting the various
CCN3 proteins (sNH25, sMNH25, sMNH24, sMNH35 and
sMNH45, see above). In addition, cell culture supernatants
from G540 and NCI-H295R cells were directly incubated
with heparin Sepharose beads (Amersham – GE Health-
care) overnight at 4°C on a rotating wheel. Beads were then
extensively washed with PBS, resuspended in Laemmli
buffer and boiled for 10 min.
Human glioblastoma G540 and G59 parental cells were
lysed in 50 mM Tris hydrochloride, pH 8.0, 150 mM NaCl,
5 mM EDTA and 2% NP40, containing protease inhibitors
(Complete mini tablets, Roche) and phosphatase inhibitors
(50 mM sodium fluoride, 2 mM sodium orthovanadate) for
30 min at 4°C. Cell debris were removed by centrifugation at
15,000×g. The protein content of the cell lysates was
measured using the BCA Protein Assay kit (Pierce). Lysates
were stored at −80°C until use. The CCN3 proteins
contained in the various lysates were immuno-precipitated
using protein A coupled to magnetic beads. Briefly, Bio-
Adembeads Protein A (Ademtech France) magnetic beads
were coated and chemically cross-linked with each anti-NH
IgG according to the manufacturer’s instructions. Of the
G540 or G59 cell lysates, 10–20 μg were incubated with
the Bio-Adembeads Protein A-antibodies for 30 min, and
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subsequently washed with the lysis buffer. Immunoprecipi-
tated proteins from cell extracts were eluted from magnetic
beads with 20 μl of 50 mM glycine pH 2.7 containing
0.65% Tween 20. After neutralization with Tris 1 M pH 8,
proteins were denaturated by boiling for 10 min in
Laemmli buffer containing 5% 2-mercaptoethanol before
gel analysis.
Proteins were separated by SDS-PAGE and transferred
onto nitrocellulose membranes (Hybond-C extra, Amer-
sham – GE Healthcare). Membranes were blocked with 5%
non-fat milk in PBS-0.2% Tween 20 (Sigma; PBST;
blocking solution) and incubated under gentle agitation
for 1 h at room temperature in the presence of the anti-NH
IgGs diluted in blocking solution. Optimal concentrations
were 25 μg/ml for anti-NH2, 8.7 μg/ml for anti-NH3,
60 μg/ml for anti-NH4, 3.8 μg/ml for anti-NH5. The blots
were extensively washed with PBST and incubated under
gentle agitation with goat anti-rabbit IgG conjugated with
horseradish peroxidase (1/20,000; Sigma) in blocking
solution for 45 min at room temperature. After extensive
washes with PBST, the membranes were developed using
the Uptima chemoluminescent kit from Interchim.
Fig. 2 Western blot analysis of
recombinant secreted CCN3
variants. a Schematic diagram
depicting the CCN3 constructs
and the nomenclature used in
this experiment. The table on the
right summarizes the reactivity
observed with each anti-NH IgG
in b (positive sign, anti-NH IgG
recognizes the corresponding
protein; negative sign, no detec-
tion). b Supernatants were col-
lected from human gliobastoma
G59 cell cultures expressing
either non-tagged full-length
CCN3 protein (sNH25 from
G540 cells; lane 1), or tagged
full-length CCN3 (sMNH25;
lane 2), or variants lacking one
or several modules: sMNH24
(lane 3), sMNH35 (lane 4),
sMNH45 (lane 5). Of each
individual CCN3 module puri-
fied from yeast culture super-
natants, 100 ng were also loaded
onto the gels (Y-NH2, Y-NH3, Y-
NH4, Y-NH5; lane 6). Secreted
proteins were analyzed by
Western blotting with each of
the four anti-NH IgG at the
concentration of 25 μg/ml for
anti-NH2, 8.7 μg/ml for anti-
NH3, 60 μg/ml for anti-NH4,
and 3.8 μg/ml for anti-NH5.
c Detection of intracellular
CCN3 forms. Cell lysates of
G540 cells and G59 parental
cells were immunoprecipitated
with each purified anti-NH IgG
coupled to protein A-magnetic
beads. Eluted proteins were
electrophoresed under denatu-
rating conditions and immuno-
blotted with each corresponding
antibodies
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Immunofluorescence staining
G59 andBHK21 cells were plated on 12mmØ coverglasses in
24-well dishes, and were transiently transfected with either
pCMV47, pcDNA, pNH25 or pNH35DsRed as described
above. pCMV47 allows the expression of full-length CCN3
protein (Bleau et al. 2007). pNH25 and pNH35DsRed govern
the expression of intracellular forms of CCN3 (Planque et al.
2006). Forty eight hours after transfection, the coverslips
were fixed with PBS containing 4% paraformaldehyde for
30 min at 4°C, and permeabilized for 5 min with PBS
containing 0.1% Triton X-100. Coverslips were sequentially
incubated with PBS containing 5% FCS for 1 h at room
temperature, incubated with primary antibodies (anti-NH IgG,
dilution 1:1,000) for 1 h in PBS containing 5% FCS, rinsed
four times with PBS, incubated with secondary antibodies
(AlexaFluor 488 goat anti-rabbit, Molecular Probe, dilution
1:2,000) for 30 min, rinsed four times with PBS, and finally
mounted in FluoroGard antifade mounting medium (Biorad).
Pictures were captured with a Leica DMR microscope.
OS7 and OS9 osteosarcoma cell lines which express
various levels of CCN3 (Lazar et al. manuscript in
preparation) were seeded in Iscove’s Modified Dulbecco’s
Medium (IMDM) 10% FCS and grown on coverslips for
48 h before being fixed in 4% para-formaldehyde 30 min at
4°C and permeabilized with 0.15% Triton X-100 in PBS.
All preparations were incubated with PBS containing 4%
BSA to saturate non-specific binding. Immunofluorescence
staining for CCN3 was performed with the following
primary antibodies: -K19M, -NH2, -NH3, -NH4, -NH5 all
diluted 1:200 with 4% BSA/PBS at 4°C overnight. Slides
were incubated with secondary antibody (CY3-conjugated
anti-rabbit IgG, Sigma; 1:5,000 dilution) for 1 h at room
temperature. Nuclei were stained with Hoechst 33258
(0.5 μg/ml PBS/glycerol, Sigma). Digital images were
taken in identical conditions, by using the image analysis
software (Quips-XL genetic workstation, Abbot Visys).
Immunohistochemistry
Samples of normal embryonic (16 and 28 weeks gestation),
fetal, and adult kidneys, were included in a Tissue Micro
Array (TMA). TMA sections of 5 μm were deparafinized
and antigen retrieval was performed by incubating the tissue
sections with citrate buffer (pH 6.0) in a pressure cooker at
1.5 ATM for 3 min. The endogenous peroxidase was
blocked using 3% hydrogen peroxidase for 5 min at room
temperature. For immunohistochemistry the purified anti-
bodies were used at the following dilutions: anti-NH2, anti-
NH3, and anti-NH4 (1:400), anti-NH5 (1:600), anti-K19M
(1:800). The immunohistochemical procedure included
incubation of primary antibodies for 1 hour, immunodetec-
tion using ChemMate™ DAKO ENVISION™ /HRP Rabbit/
Mouse (ENV) system followed by revelation of the reaction
product by exposure to 3,3’-diaminobenzidine chromogen.
Normal fetal kidneys specimens not treated by the primary
antibodies were used as control. The levels of CCN3
immunostaining were evaluated independently by three
investigators (MMS, SN and ALB).
Results
Production and purification of anti CCN3 module
antibodies
E. coli BL21 cells, transformed with the various pGEX-NH
plasmids, produced GST fusion proteins of about 38 kDa
molecular weight (corresponding to 26-kDa of GST plus 9,
10, 11, and 12 kDa of NH2, NH3, NH4, and NH5,
respectively; Fig. 1a). Fusion proteins were purified from
bacterial lysates by a single-step affinity chromatography
on glutathione-Sepharose beads and quantified as described
under “Material and methods.” The purity of each GST
fusion preparation was determined by Coomassie blue
staining of the proteins separated by SDS-PAGE (Fig. 1b).
Polyclonal anti NH IgGs were produced in rabbits after
injection. For each construct, rabbits were injected with a
total of 1.5 mg of fusion protein. All sera were treated
separately. The concentrations of anti-module specific IgGs
obtained after two successive rounds of affinity chromatog-
raphy (see “Material and methods”) were as follows: anti-
NH2: 10 mg/ml; anti-NH3: 7 mg/ml; anti-NH4: 12 mg/ml;
anti-NH5: 3.8 mg/ml.
These preparations were tested for their ability to detect
various full-length and truncated forms of the human CCN3
protein under both denaturating and native conditions.
Western blot analysis of eukaryotic cell supernatants
and cell extracts
Recombinant CCN3 proteins that were purified from
yeast culture media and from G540-conditioned cell
culture medium were used to assess the sensitivity and
specificity of the module-specific antibodies. The G540
conditioned medium contains both the full-length 54 kDa
(Gupta et al. 2001; Bleau et al. 2007) and the 32 kDa
amino truncated human CCN3 proteins (Kyurkchiev et al.
2004). Each of the CCN3 modules was produced in yeast,
as described under Materials and Methods. The proteins
contained in the yeast culture media were purified either
by immuno-affinity chromatography, or by imidazol-
affinity chromatography.
Western blot analysis revealed that each anti-NH
antibody detected the individual CCN3 modules produced
in yeast (Y-NH; Fig. 2b, lane 6), as well as the full-length
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protein (sNH25) secreted by the G540 cells (Fig. 2b, lane 1).
The band of high molecular weight that is detected in the
Y-NH5 preparation with the anti-NH5 antibodies (Fig. 2b,
lower right panel, lane 6) is thought to result from
oligomerization driven by the CT module (Perbal and
Planque 2006). Similar high molecular CCN3 species were
observed in patients with AML (McCallum et al. 2006) and
were shown to be directly related to the level of expression
of CCN3 in these patients. The additional band detected by
the anti-NH5 in the conditioned medium of G540 cells
(Fig. 2b, lower right panel, lane 1) corresponds to the
32 kDa CCN3 variant that was originally identified with the
K19M antibody (Kyurkchiev et al. 2004). All the bands
detected by the anti-NH5 antibody were also detected,
though less strongly, by the K19M antibody (data not
shown). Also, the anti-NH antibodies raised against one
particular module did not react with the other three modules
produced in yeast (data not shown).
Anti-NH antibodies detected CCN3 modules within the
recombinant proteins secreted by G59 stable transfectants
expressing truncated CCN3 variants (sMNH, Fig. 2a). For
example the anti-NH2 antibodies stained sMNH25 and
sMNH24 (Fig. 2b, upper panel left, lane 2 and 3), and did
not react with the sMNH35 and sMNH45 proteins that do
not contain the IGFBP module (Fig. 2b, upper panel left,
lane 4 and 5). Anti-NH3 recognized sMNH25, sMNH24,
sMNH35, but not sMNH45 (Fig. 2b, upper panel right) and
anti-NH4 permitted the detection of all the variants
(Fig. 2b, lower panel left). As expected, anti-NH5 reacted
with all the variant proteins but sMNH24 that does not
contain the C-terminal module of CCN3 (Fig. 2b, lower
panel right).
Inasmuch as the NH antibodies showed different sensi-
tivities, the IgG concentrations used for Western blotting
needed to be adjusted for optimal staining of the various
CCN3 variants in conditioned medium (see Fig. 2b). In spite
of these adjustments, staining of sMNH24 and sMNH35
with anti-NH3 was repeatedly weak, therefore suggesting
that the VWC module is not a powerful immunogen.
Previous experiments performed with the K19M antibody
identified CCN3 proteins inside normal and tumor cells.
As a first step in examining whether intracellular CCN3
proteins were also detected by the NH antibodies, G59 and
G540 cell lysates were first immunoprecipitated with anti-
NH IgG cross-linked to Protein A coupled to magnetic beads
and further treated for Western blotting (Fig. 2c). The results
obtained indicated that the four NH antibodies detected
CCN3 proteins in the immunoprecipitate, therefore estab-
lishing that they readily reacted with native CCN3 protein.
In a second step, we assessed the ability of the NH
antibodies to recognize the human endogenous CCN3
protein. For that purpose, conditioned medium from NCI-
H295R adrenocortical carcinoma cells was used. We had
previously established that these cells naturally secrete high
levels of CCN3 proteins (Thomopoulos et al. 2001). The
54 kDa full-length CCN3 protein, was detected with the
four NH antibodies (Fig. 3a). An amino-truncated 32 kDa
CCN3 protein was also identified in the conditioned
medium of various human cell lines including NCI-
H295R (Thomopoulos et al. 2001, Perbal 2004; Kyurkchiev
et al. 2004). When straight conditioned medium was used,
only the NH5 antibody detected the 32 kDa CCN3 protein.
However, when the concentration of CCN3 proteins
contained in the medium was increased by chromatography
through heparin columns, the 32 kDa CCN3 protein was
detected by both NH4 and NH5 antibodies. This protein
was neither detected by the NH2 nor NH3 antibodies in the
heparin binding fractions (Fig. 3a) therefore suggesting that
it corresponded to a CCN3 variant lacking both the IGFBP
and VWC modules.
A similar amino-truncated CCN3 protein has previously
been identified in the culture medium of insect cells
secreting recombinant full-length CCN3 protein (Perbal et
al. 1999). Purification and sequencing revealed that this
amino-truncated form lacked both IGFBP and VWC
modules (similar to the NH45 recombinant protein used in
this work). Until now, the lack of domain-specific anti-
Fig. 3 Western blot of human endogenous CCN3 proteins in cancer
cells. a Culture supernatants from NCI-H295R cells were concentrated
with heparin Sepharose beads. Equal amounts of supernatants were
loaded onto the gel in quintuplet. Membranes were incubated with
each of the four anti-NH antibodies at their optimal concentration (see
above). Anti-K19M antibodies were used as positive control.
b Comparison of the relative sensitivity of the anti-NH antibodies.
Equal amounts of supernatant from NCI-H295R cells culture
concentrated with heparin Sepharose beads were loaded onto the gel
in quintuplet. Membranes were incubated with each of the four anti-
NH IgG and K19M antibodies at the same concentration (60 μg/ml)
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bodies, did not permit confirmation that the 32 kDa-protein
detected in various cell supernatants was indeed composed
of the TSP1 and CT modules.
When identical amounts of conditioned medium were
used with the same concentration of antibodies prepara-
tions, the anti-NH5 antibody was found to be the most
reactive and anti-NH2 the least reactive (Fig. 3b). Similar
conclusions were drawn from results obtained with purified
GST-NH25 protein (not shown).
Immunofluorescence detection of CCN3 in cultured cells
In order to determine whether the NH antibodies were able
to detect cellular CCN3 by immunofluorescence, human
glioblastoma G59 cells that express full-length CCN3 were
used. The four IgG preparations (anti-NH2, -NH3, -NH4
and -NH5) detected the human CCN3 protein in transfected
cells (Fig. 4). Positive staining was considered confirmatory
since no fluorescence signal was observed in control
pcDNA-transfected cells (Fig. 4, lower panel left and not
shown). K19M antibodies were used as positive control
(Fig. 4, lower panel right).
Intracellular CCN3 variants have been detected in the
cytoplasm and in the nucleus of cancer cells (Perbal 1999;
Fig. 5 Detection of native non-secreted CCN3 proteins in mammalian
cells by immunofluorescent staining. BHK21 cells were transiently
transfected with either pNH35DsRed (left column) or pcDNA-NH25
(right column). Both nuclear and cytoplasmic staining were detectable
in transfected cells (for the subcellular localization of the NH35DsRed
and NH25 proteins, see Planque et al. 2006)
Fig. 4 Detection of native secreted CCN3 protein in mammalian cells
by immunofluorescent staining. G59 cells were transiently transfected
with the pCMV47 vector expressing a full-length secreted form of the
human CCN3 protein (sNH25). Pictures of two independent fields are
shown for each anti-NH IgG. The K19M antibodies were used as
positive control (lower panel right). As negative control, G59 cells
were transfected with pcDNA. The background generated with the
anti-NH5 IgG is shown lower panel left
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Gellhaus et al. 2004; Fu et al. 2004). We previously
reported that CCN3 proteins deprived of signal peptide
were detected in the cell cytoplasm and routed to the
nucleus, provided that they contained the carboxy-terminal
module (Planque et al. 2006). To check whether the NH
antibodies could detect such CCN3 protein variant, BKH21
cells were transiently transfected with pNH35DsRed, that is
driving the expression of an amino-truncated form of CCN3
(NH35) fused to a carboxy-terminal Dictosoma striata Red
(DsRed) tag. The NH35 protein showed both cytoplasmic
and nuclear localization when assayed with the K19
antibodies (Planque et al. 2006). This construct also
allowed direct detection of the recombinant proteins by
auto-fluorescence of the DsRed protein.
The NH35DsRed protein was readily detected both in
the cytoplasm and the nucleus of transfected cells with the
anti-NH3, -NH4, and -NH5 antibodies (Fig. 5, left column).
It is worth noting that the anti-NH2 IgG did not recognize
the NH35DsRed protein, which does not contain the
IGFBP module, therefore reinforcing the conclusion that
labeling obtained with NH antibodies were specific (Fig. 5,
upper panel left). None of the four anti-NH IgGs cross-
reacted with the DsRed protein (not shown). Both cytoplasmic
and nuclear untagged CCN3 protein expressed in pcDNA-
NH25-transfected BHK21 cells (Planque et al. 2006) were
also detected by the four NH antibodies. The staining
obtained with the anti-NH and -K19M antibodies in these
samples were identical (Fig. 5, lower panel left) therefore
indicating that the NH antibodies could be used for the
detection of CCN3 proteins in cells (Fig. 5, right column).
In order to establish that the module-specific antibodies
also detected endogenous CCN3 proteins expressed in
human tumor cells, osteosarcoma cell lines expressing
various levels of CCN3 were used. As expected from the
results obtained from Western blotting, positive, staining
for CCN3 was detected in the cytoplasm of cells (Fig. 6).
Table 1 CCN3 immunocytochemistry on normal embryonal, fetal and adult kidney
AB Embryonal Fetal Adult
G T S G T S G T S
K-19 +++ ++ ++ +++ +++ +++ Ø +++ Ø
NC NC NC N NC NC Cg
NH2 Ø + Ø Ø Ø Ø Ø + Ø
Dc Dc
NH3 Ø + Ø Ø Ø Ø Ø ++ Ø
Dc Dc
NH4 Ø ++ + Ø +++ Ø Ø ++ Ø
Cg Cg Dc Dc
NH5 +++ +++ +++ +++ +++ +++ + ++ +
Dc NC NC NC Dc Dc Dc
AB Antibody, N nuclear staining, NC nuclear and cytoplasmic staining, Dc diffuse cytoplasmic staining, Cg cytoplasmic granular staining,
G glomeruli, T tubules, S stroma
Fig. 6 Detection of the endogenous CCN3 protein in human
osteosarcoma cells by immunofluorescent labeling. CCN3 expression
in human osteosarcoma (OS7, and OS9) cell lines was assayed by
indirect immunofluorescence using anti-NHs antibodies. Nuclei were
counterstained with DAPI
98 N. Lazar, et al.
Fig. 7 Detection of the endogenous CCN3 protein in human kidney
tissues by immunohistolabeling. Embryonic kidney (16 weeks gestation),
fetal kidney (28 weeks gestation) and normal adult kidney stained with
anti-NH2, -NH3, -NH4, -NH5 and -K19M polyclonal antibodies (×40).
Fetal kidney stained with anti-K19M. Glomerular cells, epithelial tubular
cells and interstitial cells appear intensively labeled. Fetal kidney stained
with anti-NH5, displaying intense positivity in the cytoplasms and nuclei
of the cells within the tubules as well in the glomeruli and interstitial
blastema. Embryonic kidney stained with anti-K19M presenting intense
positivity in developing glomeruli and in tubules. Embryonic kidney
showing positivity for anti-NH4 in tubules and blastemal cells.
Embryonic kidney showing intense positivity for NH5 in all tissue
components. Normal adult kidney stained with anti-K19M. Strong
positivity in tubules with a granular cytoplasmic distribution. Normal
adult kidney stained with anti-NH5. Intense positivity of almost all
cellular components
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The results obtained with anti-K19M antibody support the
specific reactivity of the NH antibodies in immunofluores-
cence (Fig. 6). Large variations in staining that were
observed with the various antibodies might result from
a different accessibility of the CCN3 epitopes in the
various cell lines, as already suggested in previous work
(Kyurkchiev et al. 2004).
In situ detection of the endogenous CCN3 protein in kidney
tissues
Because we ultimately aimed at using the anti-NH anti-
bodies to detect the various CCN3 proteins expressed in
tumor samples, the expression of CCN3 was also analyzed
by immunohistochemistry on paraffin-embedded sections
of normal human embryonic, fetal and adult kidney tissues
for which the pattern of CCN3 has already been character-
ized (Chevalier et al. 1998; Kocialkowski et al. 2001).
The results that were obtained are summarized in Table 1.
In embryonic kidney the anti-NH2 and anti-NH3 antibodies
stained only some tubular structures while the embryonic
glomeruli and the blastemal interstitial cells were negative.
Anti-NH4 also stained the tubular component of the
developing kidney (Fig. 7) while anti-NH5 demonstrated
intense positivity in almost all components of the kidney:
blastemal cells, nephrogenic vesicles, embryonic glomeruli
and most of the tubular epithelia (Fig. 7). In the fetal kidney
anti-NH4 stained the tubules while anti-NH5 displayed the
most intense positivity in all areas of the nephron
(glomeruli and tubules). Staining was both cytoplasmic
and nuclear (Fig. 7). In the adult kidneys, anti-NH2 reacted
faintly with some epithelial cells of the proximal and distal
tubules, with a granular cytoplasm distribution. The
glomeruli and the stroma were negative. The anti-NH3
stained almost all tubular structures, with variable inten-
sity in the cytoplasm of the epithelial lining while the
glomeruli did not show any reactivity. The staining
patterns for anti-NH4 and anti-NH3 were similar while a
strong positivity was observed with the anti-NH5 in the
tubules and in isolated cells within the glomerular tuft,
with diffuse or granular decoration of the epithelial cell
cytoplasm (Fig. 7).
The various staining patterns obtained with the anti-NH
antibodies matched the staining that was obtained with the
anti-K19M and were in agreement with the previous
identification of CCN3 sites of expression in the developing
and adult kidneys. In addition they also suggested that
either some CCN3 epitopes are masked in specific
structures or that CCN3 isoforms, lacking specific modules
are expressed in a developmentally regulated way in the
various kidney structures. This particular aspect is under
current investigation.
Discussion
In the past decade, several studies have reported the
existence of truncated CCN proteins in normal cells and
tumor samples (see reviews in Perbal and Takigawa 2005).
The first evidence for the expression of a truncated CCN
protein being associated with tumorigenic potential has
been provided with the discovery of CCN3 in avian
nephroblastomas (Joliot et al. 1992). Since that time,
compelling observations have accumulated suggesting a
role for amino-truncated CCN3 in tumorigenicity as the
result of nuclear localization (Perbal 1999, 2004; Planque
and Perbal 2003b; Planque et al. 2005, 2006).
The discovery of amino-truncated CCN3 highly
expressed in particular subtypes of human melanomas
(Vallacchi et al. 2007, submitted for publication) has
confirmed the biological importance of these CCN protein
variants and have raised the possibility that tumors of other
tissues might also express rearranged CCN3 proteins, as
previously shown in the case of CCN4 (Yanagita et al.
2007; Cervello et al. 2004; Tanaka et al. 2001, 2003).
Because tumor samples are generally small and precious, it
is not always possible to perform Western blotting on
protein lysates and protein analysis is often performed by
immunocytochemistry on tumor sections or tissue arrays.
Based on the variety of biological functions that depend
upon the highly conserved multimodular structure of CCN
proteins, we assumed that alteration of any single module
would have quite important biological consequences. Since
published data established that CCN3 variant species can be
generated through post translational processing (Perbal
et al. 1999; Bleau et al. 2007) we reasoned that wide
screening of tumor samples for the expression of truncated
CCN3 proteins would be eased by the use of module-
specific antibodies. In our previous studies we have
successfully used a polyclonal antibody (Anti-K19M) that
was raised against the 19 terminal amino acids of CCN3
(Chevalier et al. 1998). Even though this type of antibody
proved very powerful in identifying truncated CCN3
proteins by Western blotting, it did not permit discrimination
of full-length and truncated CCN3 proteins by immunocy-
tochemical methods performed on tissues.
In this work we have generated and characterized a set
of four polyclonal rabbit antibodies, namely anti-NH2,
-NH3, -NH4, and -NH5, raised against each of the IGFBP,
VWC, TSP1, and CT modules of CCN3, respectively. We
show that these antibodies are unique tools to detect
normal and variant CCN3 proteins by Western blotting,
immunofluorescence, and immunocytochemistry. Since
these antibodies also permit immunoprecipitations we
assume that they recognize both native and denatured
CCN3 proteins.
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Western blotting performed with conditioned medium
and lysates from cell lines expressing various recombinant
CCN3 proteins of different sizes, established that the
module-specific antibodies recognized the CCN3 modules
both as single species and when they are contained within
recombinant proteins.
Use of this new panel of antibodies established that the
32 kDa protein that was detected in conditioned medium of
CCN3 producing cells, is composed of the TSP1 and CT
domains of CCN3. As compared to the full-length protein
which is also expressed in the medium, the 32 kDa protein
is lacking the two amino-proximal modules of CCN3. A
truncated CCN3 protein with apparent molecular mass of
30–32 kDa was detected with the anti-K19M antibody in
conditioned medium from cells such as NCI H295R
(Thomopoulos et al. 2001; Kyurkchiev et al. 2004), in
different human biological fluids such as urine, amniotic
fluid, and cerebrospinal fluid (Burren et al. 1999), and in
tissue extracts (Su et al. 2001). Based on the observation
that an amino-truncated CCN3 of the same size and
composition was also detected in the conditioned medium
of SF9-infected insect cells producing recombinant CCN3
(Perbal et al. 1999) the 32 kDa detected in the conditioned
medium of higher eukaryotic cells might result from
proteolytic cleavage of the full-length 54 kDa CCN3
protein. A CCN3 protein with an apparent molecular
weight of 32 kDa is also detected in cell lysates
(Kyurkchiev et al. 2004) therefore raising the possibility
that other biological mechanisms might be involved in the
production of the amino-truncated CCN3 variant.
In spite of their different affinities for the modules they
specifically recognize, anti-NH5 being by far the most
sensitive, all module-specific antibodies also recognized the
corresponding modules within recombinant CCN3 proteins
containing various combinations of modules. These obser-
vations indicated that the detection of each CCN3 module
was not hampered by the intrinsic composition of the
rearranged CCN3 protein and confirmed that CCN3
proteins lacking various modules were not degraded.
Most interestingly, the anti-NH5 antibody readily
detected the CT domain of the native CCN3 whereas the
anti-K19M which is directed against the carboxy terminal
amino acids of the CT module did not recognize efficiently
the native protein in solution (Kyurkchiev et al. 2004).
These observations also suggest that the C terminus of the
native CCN3 protein is not accessible to antibodies either
because of structural constraints, or because it is engaged in
interaction with other partners (Perbal 2001).
The ability of the anti-NH antibodies to react with CCN3 in
cells and tissues processed for immunofluorescence and
immunocytochemistry, is a very important point towards our
goals. Because the osteosarcoma cell lines expressed high
quantity of CCN3 protein, we selected them for testing the
capacity of the NH-antibodies to assess the detection of
endogenous CCN3 protein by immunofluorescence in tumor
cells. The results that we obtained establish this methodology
as a unique tool for CCN3 evaluation in tumor samples from
patients. Only previous results indicated that CCN3 proteins
were detected by immunofluorescence using the anti-K19M
antibody in several human cancer cell lines, including HeLa,
osteosarcoma 143 and choriocarcinoma Jeg3, in rat C6 glioma
cells, as well as in some cases of osteosarcomas and Ewing’s
sarcomas (Perbal 1999; Gellhaus et al. 2004; Fu et al. 2004;
Manara et al. 2002). The immunoreactivity demonstrated by
the NH-antibodies was comparable to that of the polyclonal
antibodies specific to K19M.
The detection of CCN3 by immunohistochemistry on
paraffin-embedded sections also provided the demonstra-
tion that the anti-NH antibodies constituted a unique tool to
screen human tumors for the expression of full-length or
truncated CCN3 proteins.
In conclusion, we report here the characterization of a
new set of module-specific antibodies that permit the
structural composition of CCN3 proteins expressed in
normal and pathological conditions. The new antibodies
specifically react with the CCN3 modules contained in the
full-length and truncated CCN3 proteins, under various
experimental conditions including Western blot, immuno-
fluorescence, and immunohistochemistry. Therefore, this
set of antibodies represent unique tools to undertake wide
screening of CCN3 expression in tumor arrays and should
prove to be useful for proteomic analysis.
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